Citi analyst Joanne Wuensch maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of $160.00.
Joanne Wuensch’s rating is based on several factors influencing Abbott Laboratories’ stock. Despite a recent unfavorable development in a state case related to NEC litigation, which could be seen as a negative factor, the overall outlook for Abbott remains positive. The stock has experienced a significant increase of approximately 15% year-to-date, driven by easing concerns around NEC litigation.
Moreover, the expected share price return of 23.2% indicates a strong potential for future growth, supporting the Buy rating. While there is a negative short-term view with potential downside risks, the long-term prospects and anticipated returns justify the positive recommendation. Investors are advised to consider these factors as part of their investment decision-making process.